ABSTRACT Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of
acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some …

Interindividual variability in drug response is a major clinical problem. Polymedication and
genetic polymorphisms modulating drug-metabolising enzyme activities (cytochromes P450 …

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum
concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele
nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation …

This document was developed by the Pharmacogenomics (PGx) Working Group of the
Association for Molecular Pathology Clinical Practice Committee, whose aim is to …

Neuroendovascular techniques for treating cerebral aneurysms and other cerebrovascular
pathology are increasingly becoming the standard of care. Intraluminal stents, aneurysm …

Previous studies have reported on the relationship between gut microbiota and major
depressive disorder (MDD). However, there remain gaps in literature concerning the role of …

The past decade has seen tremendous advances in our understanding of the genetic factors
influencing response to a variety of drugs, including those targeted at treatment of …

Clinical genetic testing began over 30 years ago with the availability of mutation detection
for sickle cell disease diagnosis. Since then, the field has dramatically transformed to …